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Peptic ulcer is a common gastrointestinal disease and produces mucosa erosion. The current study assessed the abil-
ity of burdock essence to repair gastrointestinal mucosa in clinical trials. In the experimental group, two tablets of 
burdock essence (500 mg/tablet) were administered three times a day after meals and a placebo was administered in 
controls. Four weeks after drug administration, the subjects in the study underwent an assessment for the efficacy of 
burdock essence as health supplements before and after administration of the drug. The presence of gastric mucosal 
lesions was determined in all of the peptic ulcer patients using electronic endoscopy before and after taking burdock 
essence. A rapid urease test on tissue samples from ulcers was conducted to verify Helicobacter pylori infection. 
Endoscopy confirmed gastric or duodenal ulcers in 30 patients. In clinical trials of 27 patients, 20 patients took bur-
dock essence; 17 (85%) recovered completely and three (15%) did not. Of the seven patients who took placebos, five 
(71%) did not completely recover and two (29%) recovered. In the experimental group, the ulcer wounds of the three 
patients who had taken burdock essence did not completely heal, but wounds were reduced in size by 30%, 75%, and 
33%. Moreover, 10 out of 11 patients who originally were positive for H. pylori infections no longer had the pathogen 
by the end of the trial. These results indicate that burdock essence has an inhibitory effect on H. pylori. This study 
confirms that two tablets (500 mg/tablet) of burdock essence taken orally three times a day after meals can help 
abolish H. pylori infection and promote the therapeutic effect of conventional medication on gastric mucosal repair 
in gastrointestinal ulcer patients.
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Introduction
Peptic ulcers are a very common digestive disease. 
A total of 5−10% of the population has peptic ulcers.1 
In Taiwan, approximately 1 million people have 
sought medical treatment and have taken medica-
tion for peptic ulcers. Moreover, peptic ulcer-related 
gastric cancer ranked fifth among the top 10 causes 
of cancer deaths in 2005, which represents a poten-
tial crisis and a huge medical burden. Following the 
discovery of Helicobacter pylori by Marshall and 
Warren in 1982,2 peptic ulcer treatment underwent a 
major change. It was finally established that H. pylori 
infection is associated with numerous diseases and 
is the main cause of peptic ulcers. Approximately 
95% of duodenal ulcers and 70% of gastric ulcers are 
associated with H. pylori leading to changes in treat-
ment, from traditional surgery to drug-based inter-
nal medicine.3 Studies have shown that in peptic 
ulcers with H. pylori infection, failure to eradicate 
H. pylori results in a recurrence rate of 60−95% 
after stopping medication.4 In contrast, if H. pylori 
is eradicated, the recurrence rate is reduced to 20%. 
Clinically, it is, therefore, generally believed that 
as soon as an H. pylori infection is identified, erad-
ication therapy should be administered.
To treat an H. pylori infection, routine clinical 
medical intervention is carried out, and specific acid 
drugs are combined with antibiotics (including amox-
icillin, tetracycline, and clarithromycin).5 However, 
side effects such as allergies, nausea, bloating and 
general fatigue may be experienced.6 In addition, 
long-term antibiotic use can also result in the ac-
cumulation of antibiotics inside the body. Comple-
mentary approaches may alleviate the discomfort 
felt by a patient, and therefore, a physician or pa-
tient may consider these as options.
Burdock (Arctium lappa L.) is an herbaceous plant 
of the Asteraceae family. Burdock roots are similar in 
shape to those of ginseng, and the Japanese, the 
world’s longest-living people, incorporate burdock 
into the diet because of its high nutritional value. It 
is rich in its nutritional composition including insulin, 
polyphenols, chlorogenic acid, protein, carbohydrate, 
vitamin groups, amino acids, minerals, and unsatu-
rated acids. Its carotene content is 150 times higher 
than that of a carrot, and it contains high levels of 
amino acids.7,8 According to many studies, aglycone 
in burdock is an active ingredient that inhibits urinary 
protein excretion, and can improve serum biochem-
ical indicators.9,10 It also demonstrates antinephritic 
activity, and can be used to treat acute nephritis, 
nephrotic syndrome, and prevents senile demen-
tia.11,12 The burdock plant contains antibacterial in-
gredients, which have shown the ability to inhibit 
Staphylococcus species and show different degrees 
of inhibitory action against a variety of pathogenic 
fungi.13−15 Moreover, the ingredients of burdock have 
been demonstrated to reduce acid-induced chronic 
gastric ulcers by 52%, reduce oxidative stress and cell 
injury in liver cells,9,10 and show antitumor activity.16 
To verify the efficacy of burdock-processed foods 
as supplements for medication, this study assessed 
whether burdock essence is able to promote gas-
trointestinal repair in peptic ulcer patients.
Materials and Methods
Testing burdock
In this study, we tested burdock essence in tablets 
at concentration of 500 mg/tablet. The Dong Yuan 
Biotech Pharmaceutical Co., Ltd. commissioned the 
Ko Da Pharmaceutical Co., Ltd. to manufacture proc-
essed food from burdock (the sample). The sample 
underwent a quality assurance test conducted by 
Tajen University and then passed the commissioned 
safety assessment test conducted by Taipei Medical 
University. The sample was consistent with the norms 
stipulated by the Health Food Management Law 
and the request for certification of burdock as a 
health food was accepted (No. A00139, letter of the 
Department of Health, Executive Yuan).
Patient selection and specimen collection
The clinical trials in this study included patients in 
the Division of Gastroenterology, Pingtung Christian 
Hospital. A total of 30 case studies were included 
in the study. Patients had to be aged 20−80 years 
with endoscopic confirmation of gastric or duodenal 
ulcers, and a lesion size ranging from 0.5−2.0 cm. 
Those patients undergoing treatment or suffering 
from severe systematic diseases, including chronic 
obstructive pulmonary disease, congestive heart fail-
ure and malignant tumors, were excluded. Those 
who were accepted after receiving a detailed expla-
nation were asked to sign a consent form. A double-
blind experiment was then carried out for all patients 
who continued in an original treatment approach. 
Two tablets of burdock essence (500 mg/tablet) were 
orally administered in the experimental group three 
times a day after meals, while the control group was 
given a placebo. During the experimental period, 
the subjects were required to take medication for 4 
weeks and undergo various tests (described below) 
before and after drug administration to assess the 
efficacy of burdock essence.
Gastric mucosal damage index analysis
Gastric mucosal lesions of peptic ulcer patients 
were examined by electronic endoscopy (GIF-Q260; 
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Olympus Corp; Tokyo, Japan). The gastric mucosal 
lesions were then photographed using an electronic 
endoscope to compare the gastric mucosa damage 
ulcer index with the naked eye.
Identification of H. Pylori infection
A rapid urease test was conducted on all tissue sam-
ples removed from the peptic ulcer patients through 
electronic endoscopy at the time of the examination. 
Test results of “pink” and “yellow” signified positive 
and negative H. pylori infection, respectively.
Table 1 Age and sex of the cases included in the study
 Experiment  
Control (placebo) 
 (burdock essence)  
 group 
group
Patients, n 20  7
Average age (yr) 56 60
Sex
 Male 15  3
 Female  5  4
Table 2 Electronic endoscopy and urease test results for the burdock essence experimental group
Patient
  
Age
 Electronic endoscopy clinical signs Helicobacter pylori infection
 Sex  Degree of ulceration  Urease test Urease test
    before intake/after Ulcer index*  before  after no.
  
 (yr)
  intake (cm)   intake  intake
 1 Male 54 Du 0.8 cm/0 cm Completely healed Negative Negative
 2 Male 77 Gu 1.2 cm/0 cm Completely healed Negative Negative
 3 Male 49 Du 0.3 cm/0 cm Completely healed Negative Negative
 4 Male 64 ND Completely healed Negative Negative
 5 Male 41 ND Completely healed Negative Negative
 6 Male 35 ND Completely healed Negative Negative
 7 Male 56 ND Completely healed Negative Negative
 8 Male 55 Gu 0.6 cm/0.1−0.2 cm Nearly healed Negative Negative
 9 Female 50 Du, exposed vessel/ Completely healed Negative Positive
    ulcer scar
10 Male 49 Gu 1.5 cm/0 cm Completely healed Positive Negative
11 Male 69 Du 1.2 × 0.6 cm/0 cm Completely healed Positive Negative
12 Male 77 Gu 0.6 cm/0 cm Completely healed Positive Negative
13 Male 44 Du 0.6 cm/0 cm Completely healed Positive Negative
14 Female 67 Gu 0.8 cm/0 cm,  Completely healed Positive Negative
    Gu 0.4 cm/0 cm, 
    Du 0.5 cm/0 cm
15 Female 45 Gu 1.2 cm/0 cm Completely healed Positive Negative
16 Female 70 Gu 0.5 cm/0 cm,  Completely healed Positive Negative
    Du 0.6 cm/0 cm
17 Male 39 Du 1.5 cm/0.2 cm Nearly healed Positive Negative
18 Female 64 Gu 2.0 cm/lines 0.6 cm Nearly healed Positive Negative
19 Male 58 Du 0.8 cm/ulcer scar Completely healed Positive Positive
20 Male 56 Gu 1.8 cm/0 cm Completely healed Positive Negative
*Stock market risk measure or technical analysis indicator devised by Peter Martin in 1987.17 Du: duodenal ulcer; Gu: gastric ulcer; 
ND = not done.
Results
Endoscopy confirmed that the 30 patients enrolled 
in the study had gastric or duodenal ulcers, and the 
experiment begun after patient consent. Among 
the 30 patients, three could not undergo follow-up 
examinations. Of the three patients, one failed to 
make the subsequent scheduled visit (experimental 
group), the family of the second patient did not 
approve of the experiment (experimental group), 
and the third patient withdrew owing to lower ex-
tremity edema (placebo group). At the conclusion 
of the burdock essence clinical trials, the remaining 
27 patients were included in the statistical analysis. 
The clinical trial included 27 patients with an age 
range of 35−77 years and an average age of 57. 
Eighteen patients were male and nine were female 
(Table 1).
With regard to the gastric mucosal damage 
index, of the 20 patients who had taken burdock es-
sence, 17 (85%) healed completely and three (15%) 
did not (Table 2 and Figure 1). Moreover, among the 
seven patients who had taken placebos, five (71%) 
were not completely healed and two (29%) were 
completely healed. Three patients in the burdock 
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essence experimental group had ulcer wounds that 
did not heal completely; however, their ulcer dam-
age was reduced by 30%, 75%, and 33% (Table 2 and 
Figure 2). Urease test results showed that the 
patients designated 1 through 8 in the burdock 
essence experimental group tested negative for 
H. pylori infection either before or after the trial. 
Patients designated as numbers 9 and 19 tested 
positive for H. pylori infection, but their gastric 
ulcer repair showed improvement in scab forma-
tion. Patients 10 through 18, and patient 20 were 
positive for H. pylori infection before the trial, while 
urease tests for H. pylori infection had a negative 
result after the trial (Tables 2 and 3). The gastric mu-
cosal damage index results and the H. pylori test 
suggested that burdock essence promoted gastroin-
testinal mucosal healing in patients with gastric or 
duodenal ulcers, and improved the effect of medi-
cation on the suppression of H. pylori infection.
Discussion
Our findings suggest that the scope of applications 
for the use of burdock essence should include healthy 
individuals and patients experiencing gastrointesti-
nal discomfort. Because of modern-day eating habits, 
which include processed, low-fiber and fast food, 
people face the considerable threat of suffering from 
gastrointestinal diseases. Intake of burdock essence 
Figure 1 Electronic endoscopy shows the gastric mucosa damage index of the burdock essence in a representative 
patient in the experimental group. (A) Clinical photographs of the degree of mucosal damage before intake. The 
ulcer wound is approximately 1.5 cm. (B) Clinical photographs of the change in the degree of mucosal repair after the 
trial. The ulcer wound is completely healed. These results show that the degree of gastric mucosa repair and healing 
was improved after intake of burdock essence compared with before intake.
A B
Figure 2 Electronic endoscopy shows the gastric mucosa damage index of a representative patient in the placebo 
group. (A) Clinical photographs of the degree of mucosal damage before intake. The ulcer wound is approximately 
2.0 cm. (B) Clinical photographs of the change in the degree of mucosal repair after the trial. The ulcer wound has 
nearly healed but 1.0 × 0.5 cm of this ulcer has not healed. These results show that the degree of gastric mucosa 
repair and healing was not significantly improved after the intake of placebo.
A B
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products daily in suitable quantities may benefit 
healthy individuals by protecting their gastrointes-
tinal tract from damage by oily foods, life stresses, 
and even H. pylori, consequently reducing the risk of 
gastrointestinal diseases (i.e. disease prevention). 
According to several medical reports,18−20 most gas-
tric ulcer patients are infected with H. pylori, and 
after eliminating this infection, reoccurrence of gas-
tric ulcers is rare. Burdock essence has been shown 
to induce H. pylori antibodies in the blood serum 
and inhibit H. pylori in in vitro tests.21−24
The results of the present study indicate the ef-
ficacy of burdock essence in peptic ulcer disease. 
Our data showed that in most patients who were 
given burdock essence, 85% were completely healed. 
On the other hand, we also found that most of the 
patients who took placebos were not completely 
healed. Several of the patients in the burdock es-
sence group also had a reduction in size of their 
wounds. In addition, in the burdock essence group, 
almost all of the patients who were positive for 
H. pylori (91%) were negative for H. pylori after the 
trial, indicating that burdock essence aids in the 
inhibition of H. pylori. In summary, taking two tab-
lets (500 mg/tablet) of burdock essence three times 
a day after meals promotes gastric mucosal repair 
in gastrointestinal ulcer patients, and augments the 
inhibitory effect of the original medication on 
H. pylori. Therefore, this processed food of botanical 
origin may be beneficial for use as a supplement in 
treating patients with gastrointestinal discomfort. 
Moreover, burdock essence may potentially become 
a health food supplement used to prevent the recur-
rence of peptic ulcer disease.
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